These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 31596963)

  • 1. Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies.
    Smalls DJ; Kiger RE; Norris LB; Bennett CL; Love BL
    Pharmacotherapy; 2019 Dec; 39(12):1190-1203. PubMed ID: 31596963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
    De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
    J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients.
    Tseng CW; Liu WC; Ko PH; Chen YC; Tseng KC; Chang TT
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C.
    Aggeletopoulou I; Konstantakis C; Manolakopoulos S; Triantos C
    World J Gastroenterol; 2017 Jun; 23(24):4317-4323. PubMed ID: 28706414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
    Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B Reactivation in Patients Treated with Direct-Acting Antivirals for Hepatitis C.
    Toka B; Köksal AŞ; Dertli R; Şirin G; Fidan S; Ülger Y; Harmandar F; Yıldırım AE; Eminler AT; Asil M; Kayar Y; Bıyık M; Kuran S; Uslan MI; Hülagü S
    Dig Dis; 2022; 40(5):635-643. PubMed ID: 35108715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.
    Holmes JA; Yu ML; Chung RT
    Expert Opin Drug Saf; 2017 Jun; 16(6):651-672. PubMed ID: 28471314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
    Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
    J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.
    Serper M; Forde KA; Kaplan DE
    J Viral Hepat; 2018 Feb; 25(2):187-197. PubMed ID: 28845882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of psoriasis patients with hepatitis B or hepatitis C virus infection.
    Bonifati C; Lora V; Graceffa D; Nosotti L
    World J Gastroenterol; 2016 Jul; 22(28):6444-55. PubMed ID: 27605880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened.
    Tavakolpour S; Alavian SM; Sali S
    Hepat Mon; 2016 Apr; 16(4):e35810. PubMed ID: 27257429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review.
    Gentile G; Antonelli G
    Viruses; 2019 Nov; 11(11):. PubMed ID: 31717647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
    Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A
    Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations.
    Piaserico S; Messina F; Russo FP
    Am J Clin Dermatol; 2019 Dec; 20(6):829-845. PubMed ID: 31222626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis.
    Chen G; Wang C; Chen J; Ji D; Wang Y; Wu V; Karlberg J; Lau G
    Hepatology; 2017 Jul; 66(1):13-26. PubMed ID: 28195337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.
    Yeh ML; Huang CF; Hsieh MH; Ko YM; Chen KY; Liu TW; Lin YH; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CI; Huang JF; Kuo PL; Dai CY; Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2017 Oct; 32(10):1754-1762. PubMed ID: 28230928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    Kawagishi N; Suda G; Onozawa M; Kimura M; Maehara O; Ohara M; Izumi T; Umemura M; Ito J; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    J Viral Hepat; 2017 Dec; 24(12):1098-1106. PubMed ID: 28632923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents.
    Juan J; Feld JJ
    Curr Opin Rheumatol; 2014 Jul; 26(4):395-403. PubMed ID: 24841230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.
    Loomba R; Liang TJ
    Gastroenterology; 2017 May; 152(6):1297-1309. PubMed ID: 28219691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.